| oxaliplatin / Generic mfg. |
| Completed | 2b | 198 | US, Europe, RoW | Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin), Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin) | Bayer, Amgen | Metastatic Colorectal Cancer | 01/11 | 02/12 | | |
|
| Terminated | 2b | 191 | Japan, US, Europe | sunitinib, Sutent, SU011248, mFOLFOX6, bevacizumab, Avastin | Pfizer | Colorectal Neoplasms | 07/11 | 07/11 | | |
NCT00004102: Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer |
|
|
| Completed | 2 | | US | FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin | NYU Langone Health, National Cancer Institute (NCI) | Colorectal Cancer | 11/01 | | | |
NCT00006015: Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer |
|
|
| Terminated | 2 | 26 | US | trastuzumab, Herceptin, fluorouracil, 5-FU, leucovorin calcium, oxaliplatin | National Cancer Institute (NCI) | Colorectal Cancer | 12/02 | 02/03 | | |
NCT00026299: Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer |
|
|
| Completed | 2 | 14 | US | ZD1839, gefitinib, Iressa ®, oxaliplatin, Eloxatin ® | University of Chicago, National Cancer Institute (NCI) | Colorectal Cancer | 12/02 | 02/05 | | |
NCT00016198: Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer |
|
|
| Completed | 2 | | US | FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin | Prologue Research International | Colorectal Cancer | 04/03 | 12/10 | | |
NCT00017082: Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer |
|
|
| Completed | 2 | | US | oxaliplatin | Prologue Research International | Colorectal Cancer | 06/03 | 12/10 | | |
NCT00044343: GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin |
|
|
| Completed | 2 | 80 | US, Canada | lapatinib | GlaxoSmithKline | Colorectal Cancer | 10/03 | 10/03 | | |
NCT00065117: Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer. |
|
|
| Terminated | 2 | 180 | US | ZD6126, Placebo, 5-fluorouracil, leucovorin, oxaliplatin | AstraZeneca | Colorectal Neoplasms, Metastases, Neoplasm | 02/04 | 02/04 | | |
NCT00016952: Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 19 | US, Canada | fluorouracil, irinotecan hydrochloride, leucovorin calcium | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer | 04/04 | 10/09 | | |
NCT00070265: Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer |
|
|
| Terminated | 2 | 80 | US | oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, capecitabine, CAPE, Ro 09-1978/000, Xeloda, therapeutic conventional surgery, laboratory biomarker analysis | National Cancer Institute (NCI) | Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer | 09/04 | | | |
NCT00077987: Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments. |
|
|
| Completed | 2 | 84 | NA | SU011248 | Pfizer | Colorectal Neoplasms | | 04/05 | | |
NCT00080951: Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 14 | US | fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer | 04/05 | 02/08 | | |
NCT00399750: TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer |
|
|
| Completed | 2 | 373 | US | oxaliplatin, fluoropyrimidine, bevacizumab | Sanofi | Colorectal Cancer | | 06/05 | | |
NCT00039208: Combination Chemotherapy in Treating Patients With Colorectal Cancer |
|
|
| Completed | 2 | | Europe | fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin | European Organisation for Research and Treatment of Cancer - EORTC | Colorectal Cancer | 08/05 | | | |
SAKK 41/04, NCT00227734: Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery |
|
|
| Completed | 2 | 74 | Europe | capecitabine and oxaliplatin + cetuximab, capecitabine and oxaliplatin | Swiss Group for Clinical Cancer Research | Colorectal Cancer | 10/05 | 02/06 | | |
NCT00003834: Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer |
|
|
| Completed | 2 | 44 | US, Canada | fluorouracil, leucovorin calcium, oxaliplatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer, Metastatic Cancer | 12/05 | 12/05 | | |
NCT00026234: Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver |
|
|
| Completed | 2 | 75 | US | floxuridine, 5-FUDR, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, capecitabine, CAPE, Ro 09-1978/000, Xeloda | National Cancer Institute (NCI), NSABP Foundation Inc | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer | 01/06 | | | |
NCT00268333: Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 39 | Europe | fluorouracil, leucovorin calcium, oxaliplatin, neoadjuvant therapy | GERCOR - Multidisciplinary Oncology Cooperative Group | Colorectal Cancer | 01/06 | | | |
NCT00070434: S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum |
|
|
| Withdrawn | 2 | 0 | US | capecitabine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin, radiation therapy, Pyridoxine | Southwest Oncology Group, National Cancer Institute (NCI) | Colorectal Cancer | 02/06 | | | |
| Completed | 2 | 200 | US | ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen) | Mayo Clinic | Locally Advanced Unresectable or Stage IV Colorectal Cancer | 06/06 | 06/06 | | |
NCT00120172: Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer |
|
|
| Terminated | 2 | 40 | US | oxaliplatin, capecitabine, bevacizumab | Geriatric Oncology Consortium, Sanofi | Colorectal Cancer, Neoplasm Metastasis | | 06/06 | | |
NCT00103298: Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer |
|
|
| Completed | 2 | | US | FOLFOX regimen, fluorouracil, isolated perfusion, leucovorin calcium, melphalan, oxaliplatin | National Cancer Institute (NCI) | Colorectal Cancer, Metastatic Cancer | | 07/06 | | |
NCT00123851: Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 32 | US | Tarceva (OSI-774), Capecitabine, Oxaliplatin | Dana-Farber Cancer Institute, Sanofi-Synthelabo, OSI Pharmaceuticals, Hoffmann-La Roche, Genentech, Inc., Massachusetts General Hospital, Beth Israel Deaconess Medical Center | Colorectal Cancer, Neoplasm Metastasis | 08/06 | 08/06 | | |
NCT00378066: Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer |
|
|
| Completed | 2 | 49 | RoW | Bevacizumab, Capecitabine, Oxaliplatin | Asan Medical Center | Metastatic Colorectal Cancer | 08/06 | 10/08 | | |
NCT00262808: GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer |
|
|
| Completed | 2 | 50 | US | sargramostim, fluorouracil, leucovorin calcium, oxaliplatin, adjuvant therapy, conventional surgery, neoadjuvant therapy | University of Rochester | Colorectal Cancer | 09/06 | 09/06 | | |
NCT00276861: Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer |
|
|
| Terminated | 2 | 10 | US | gemcitabine hydrochloride, oxaliplatin | University of Miami | Colorectal Cancer | 09/06 | 05/08 | | |
NCT00025142: Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer |
|
|
| Completed | 2 | | US | FOLFOX regimen, fluorouracil, gefitinib, leucovorin calcium, oxaliplatin | Stanford University, National Cancer Institute (NCI) | Colorectal Cancer | | 11/06 | | |
NCT00254137: Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer. |
|
|
| Completed | 2 | 92 | Europe | capecitabine, irinotecan, oxaliplatin, cetuximab | Ludwig-Maximilians - University of Munich, Merck Sharp & Dohme LLC, Sanofi, Pfizer, Hoffmann-La Roche | Metastatic Colorectal Cancer | | 11/06 | | |
NCT00311610: Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 30 | US | SN-38 liposome | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer | 01/07 | 06/10 | | |
PROCTFUL, NCT00263029: Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer |
|
|
| Completed | 2 | 18 | RoW | Oxaliplatin, Capecitabine, Radiotherapy | Sanofi | Rectal Neoplasms | 03/07 | | | |
OPUS, NCT00125034: Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC) |
|
|
| Completed | 2 | 344 | Europe, RoW | Cetuximab, Oxaliplatin | Merck KGaA, Darmstadt, Germany | Neoplasm Metastasis, Colorectal Cancer | 03/07 | 11/10 | | |
|
|
|
|
|
NCT00118105: S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | bevacizumab, Avastin, NSC-704865, capecitabine, Xeloda, NSC-712807, oxaliplatin, NSC-266046, conventional surgery | Southwest Oncology Group, National Cancer Institute (NCI), Eastern Cooperative Oncology Group | Colorectal Cancer, Metastatic Cancer | 04/07 | 04/07 | | |
NCT00083616: Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy |
|
|
| Completed | 2 | 185 | US | Panitumumab, ABX-EGF, Vectibix | Amgen | Colorectal Cancer, Metastatic Cancer | 05/07 | 12/08 | | |
NCT00346099: Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum |
|
|
| Withdrawn | 2 | 0 | US | Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by, Panitumumab with capecitabine and radiation | NSABP Foundation Inc, Amgen | Rectal Cancer, Neoplasm Metastasis | | 05/07 | | |
NCT00016978: Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan |
|
|
| Completed | 2 | 40 | US, Canada | FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin | National Cancer Institute (NCI) | Colorectal Cancer | 06/07 | | | |
NCT00043004: Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer |
|
|
| Terminated | 2 | 119 | Europe, RoW | bevacizumab, FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin, conventional surgery, radiofrequency ablation | European Organisation for Research and Treatment of Cancer - EORTC, Arbeitsgruppe Lebermetastasen und Tumoren, Institute of Cancer Research, United Kingdom | Colorectal Cancer, Metastatic Cancer | 06/07 | | | |
NCT00215982: Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer |
|
|
| Completed | 2 | 24 | US | capecitabine, XELODA™, Oxaliplatin, E LOXATIN™, Irinotecan, CAMPTOSAR™ | H. Lee Moffitt Cancer Center and Research Institute, Roche Pharma AG | Colorectal Cancer | 07/07 | 07/07 | | |
NCT00385021: ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer |
|
|
| Terminated | 2 | 20 | US | 5-Fluorouracil, leucovorin, oxaliplatin, avastin | Southwestern Regional Medical Center | Colorectal Neoplasms | | 09/07 | | |
NCT00056030: Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer |
|
|
| Completed | 2 | 73 | US | cetuximab, fluorouracil, leucovorin calcium, oxaliplatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer, Metastatic Cancer | 10/07 | | | |
| Completed | 2 | 150 | Europe, RoW | Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan, FOLFOX 6, FOLFIRI | Central European Cooperative Oncology Group | Metastatic Colorectal Cancer | | 10/07 | | |
NCT00192075: A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 84 | US | Gemcitabine, Gemzar, avastin, 5FU/folinic acid, oxaliplatin | Eli Lilly and Company | Colorectal Cancer | | 11/07 | | |
NCT00174616: CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision |
|
|
| Completed | 2 | 87 | Europe | Oxaliplatin, capecitabine, radiotherapy | Sanofi | Rectal Neoplasms | 11/07 | 11/07 | | |
| Completed | 2 | 215 | Canada, Europe | AZD2171, cediranib, RECENTIN™, 5-fluorouracil, 5-FU, Leucovorin, Oxaliplatin, Eloxatin®, Bevacizumab, Avastin® | AstraZeneca | Colorectal Cancer | 11/07 | 10/09 | | |
NCT00416494: Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer |
|
|
| Completed | 2 | 50 | US | bevacizumab, oxaliplatin, Capecitabine | Herbert Hurwitz, MD, National Cancer Institute (NCI) | Colorectal Cancer | 01/08 | 08/14 | | |
NCT00153998: Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM) |
|
|
| Completed | 2 | 135 | Europe | Cetuximab, Liver resection, Cetuximab and FOLFIRI, Cetuximab(C225, Erbitux®, Merck KGaA), Irinotecan (irinotecan HCl, CPT-11 or Campto®, Aventis), 5-Fluorouracil (5-FU), Folinic acid (FA, i.e. Leucovorin®, Wyeth), Cetuximab and FOLFOX, Oxaliplatin (L-OHP, Eloxatin®, Sanofi-Synthelabo) | Technische Universität Dresden | Colorectal Cancer, Liver Metastases | 03/08 | | | |
|
|
|
|
NCT00381862: Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX |
|
|
| Completed | 2 | 54 | US | aprepitant, Emend, MK-869, L-758,298, L-754,030, dexamethasone, fluorouracil, 5-FU, irinotecan hydrochloride, Trade names: Camptosar®, Other names: Camptothecin-11, CPT-11, leucovorin calcium, Generic Name: Leucovorin, Other Names: Citrovorum Factor, Folinic Acid, oxaliplatin, Trade Name: Eloxatin, palonosetron hydrochloride, Aloxi, quality-of-life assessment | OHSU Knight Cancer Institute, National Cancer Institute (NCI) | Colorectal Cancer, Nausea and Vomiting | 03/08 | 07/08 | | |
NCT00454116 / 2006-005023-42: A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients |
|
|
| Completed | 2 | 106 | US, Europe, RoW | Vandetanib, ZD6474, ZACTIMA™, FOLFIRI | Genzyme, a Sanofi Company | Colorectal Cancer | 03/08 | 11/09 | | |
NCT00500292 / 2006-005022-23: A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer |
|
|
| Completed | 2 | 109 | Europe, RoW | Vandetanib, AZ6474, ZACTIMA™, SAR390530, FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid | Genzyme, a Sanofi Company | Colorectal, Cancer | 03/08 | 11/16 | | |
NCT00408772: Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | bevacizumab, capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiofrequency ablation | University of California, Davis, Sanofi | Colorectal Cancer, Metastatic Cancer | 04/08 | 04/08 | | |
NCT00345696 / 2005-006171-12: 1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR. |
|
|
| Completed | 2 | 32 | Europe | Bevacizumab, Avastin, Capecitabine, Xeloda, Oxaliplatine, Eloxatin | Unidad Integral de Investigación en Oncología S.L., Hoffmann-La Roche | Metastatic Colorectal Cancer | 10/08 | 01/11 | | |
NCT00755534: Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC |
|
|
| Terminated | 2 | 68 | Europe | Irinotecan, CPT-11, Campto, Capecitabine, Xeloda, Cetuximab, Erbitux, Oxaliplatin, Eloxatin, LoHP | Hellenic Oncology Research Group, University Hospital of Crete | Colorectal Cancer | 11/08 | 11/08 | | |
NCT00290615: Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery |
|
|
| Completed | 2 | 30 | US | bevacizumab, Avastin, cetuximab, capecitabine, oxaliplatin | Herbert Hurwitz, National Cancer Institute (NCI) | Colorectal Cancer | 01/09 | 01/11 | | |
| Completed | 2 | 136 | Europe | FOLFOX-4+cetuximab, FOLFOX-4 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Merck Sharp & Dohme LLC | Colorectal Cancer | 02/09 | 02/09 | | |
NCT00419159 / 2006-003255-20: Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy |
|
|
| Completed | 2 | 199 | US | Everolimus (RAD001), Afinitor, Zortress, Certican | Novartis Pharmaceuticals | Colorectal Cancer | 03/09 | 03/09 | | |
NCT00642603: A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer |
|
|
| Terminated | 2 | 41 | US | capecitabine [Xeloda], bevacizumab [Avastin], oxaliplatin, irinotecan | Hoffmann-La Roche | Colorectal Cancer | 03/09 | 03/09 | | |
NCT00118755: A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 435 | US | capecitabine, Oxaliplatin, bevacizumab | Hoffmann-La Roche | Colorectal Cancer | 04/09 | | | |
FOIB, NCT01163396: First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 57 | Europe | Bevacizumab, Irinotecan, Oxaliplatin, 5-fluorouracil/leucovorin | Gruppo Oncologico del Nord-Ovest | Colorectal Cancer Metastatic | 04/09 | 04/10 | | |
NCT00531115 / 2006-007062-11: Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer. |
|
|
| Terminated | 2 | 28 | Europe | cetuximab 5mg/ml | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Merck Sharp & Dohme LLC | Metastatic Colorectal Cancer | 04/09 | 04/09 | | |
NCT00386828: Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial |
|
|
| Completed | 2 | 43 | Canada | Bevacizumab: | British Columbia Cancer Agency | Advanced Colorectal Cancer | 05/09 | 05/09 | | |
XELOX-A-DVS, NCT00159432: Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer |
|
|
| Completed | 2 | 63 | US | Oxaliplatin, Eloxatin, Bevacizumab, Avastin, Capecitabine, Xeloda | University of Southern California, Hoffmann-La Roche, Genentech, Inc. | Colorectal Cancer | 06/09 | 03/13 | | |
|
NCT00422864: A Single Arm Trial of Oxaliplatin and 5FU With Concurrent Radiation in Patients With Metastatic Rectal Cancer |
|
|
| Completed | 2 | 26 | RoW | oxaliplatin, fluorouracil, leucovorin, External beam radiotherapy | Peter MacCallum Cancer Centre, Australia | Rectal Cancer | 06/09 | 01/11 | | |
| Completed | 2 | 46 | Europe | NGR-hTNF | AGC Biologics S.p.A. | Colorectal Cancer (CRC) | 06/09 | 04/13 | | |
FUTURE, NCT00439517: Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab. |
|
|
| Completed | 2 | 302 | Europe, RoW | UFOX + Cetuximab, FOLFOX4 + Cetuximab | Merck KGaA, Darmstadt, Germany | Previously Untreated Metastatic Colorectal Cancer | 06/09 | 05/12 | | |
|
|
MK-7454-003, NCT00551213: A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, ) |
|
|
| Completed | 2 | 67 | NA | Robatumumab, Irinotecan, Cetuximab, Capecitabine, FOLFOX, CAPEOX/XELOX, FOLFIRI | Merck Sharp & Dohme LLC | Colorectal Cancer | 06/09 | 06/09 | | |
NCT00327119: Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer |
|
|
| Completed | 2 | 50 | Japan | ABX-EGF (panitumumab) | Amgen | Metastatic Colorectal Cancer | | | | |
NCT00296062: Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer |
|
|
| Terminated | 2 | 12 | US | bevacizumab, capecitabine, irinotecan hydrochloride, oxaliplatin | Case Comprehensive Cancer Center, National Cancer Institute (NCI) | Colorectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 10/09 | 05/11 | | |
NCT00625183: Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma |
|
|
| Terminated | 2 | 5 | US | selenomethionine, capecitabine, oxaliplatin, laboratory biomarker analysis, pharmacological study, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy | Roswell Park Cancer Institute, National Cancer Institute (NCI) | Colorectal Cancer | 10/09 | 12/09 | | |
NCT00831181: Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer |
|
|
| Completed | 2 | 27 | US | 5-FU, fluorouracil, Oxaliplatin, Eloxatin, leucovorin, Folinic Acid, mesorectal excision | Beth Israel Medical Center | Colorectal Cancer | 11/09 | 11/09 | | |
NCT00321828: Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery |
|
|
| Completed | 2 | 90 | US | bevacizumab, fluorouracil, 5-FU, leucovorin, leucovorin calcium, oxaliplatin | NSABP Foundation Inc, National Cancer Institute (NCI) | Colorectal Cancer | 11/09 | 12/12 | | |
|
|
NCT00537823: Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement |
|
|
| Terminated | 2 | 9 | US | Cetuximab, Erbitux, Bevacizumab, Avastin, Leucovorin, Oxaliplatin, Fluorouracil | Washington University School of Medicine | Colorectal Cancer, Metastases | 12/09 | 07/11 | | |
| Completed | 2 | 44 | Europe | IMC-11F8 (necitumumab), Necitumumab, IMC-11F8, LY3012211, Portrazza®, Oxaliplatin, Folinic acid (FA), 5-FU | Eli Lilly and Company | Metastatic Colorectal Cancer | 01/10 | 10/10 | | |
NCT00613080: Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer |
|
|
| Completed | 2 | 79 | Canada, US | capecitabine, oxaliplatin, 50 mg/m^2 IV over 2 hours weekly for five weeks starting on day 1 of radiotherapy., resection, radiation therapy, FOLFOX, Oxaliplatin, leucovorin, 5-fluorouracil | Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology | Colorectal Cancer | 01/10 | 12/16 | | |
NCT00220116: Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal Cancer |
|
|
| Completed | 2 | 172 | Europe | Capecitabine, Oxaliplatin | Royal Marsden NHS Foundation Trust | Colorectal Cancer | | | | |
NCT00601198: A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer |
|
|
| Terminated | 2 | 4 | US | Amifostine, Flurouracil (5-FU), Leucovorin calcium (LV), Oxaliplatin, Bevacizumab | University of Cincinnati, MedImmune LLC, AstraZeneca | Colorectal Cancer | 01/10 | 01/10 | | |
NCT01024504: Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 46 | Europe | Oxaliplatin, Eloxatin, Capecitabine, Xeloda, Bevacizumab, Avastin | Hellenic Oncology Research Group, University Hospital of Crete | Metastatic Colorectal Cancer | 03/10 | 03/10 | | |
NCT01135498 / 2005-004662-16: A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer. |
|
|
| Completed | 2 | 90 | Europe | bevacizumab [Avastin], eloxatin, capecitabine [Xeloda], erlotinib [Tarceva] | Hoffmann-La Roche | Colorectal Cancer | 04/10 | 04/10 | | |
NCT00588900: Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab |
|
|
| Terminated | 2 | 5 | US | cediranib maleate, irinotecan hydrochloride | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer | 05/10 | 11/11 | | |
NCT00479752: Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 151 | Europe, RoW | FOLFOX4 (Oxaliplatin), Cetuximab | Central European Cooperative Oncology Group | Colorectal Cancer | 06/10 | 11/15 | | |
|
|
NCT01159171 / 2005-001012-41: A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer. |
|
|
| Completed | 2 | 50 | Europe | bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 07/10 | 07/10 | | |
NCT00421824 / 2005-005149-20: Study of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer |
|
|
| Completed | 2 | 108 | Europe | Oxaliplatin, capecitabine, Radiotherapy | Sanofi | Rectal Neoplasms | 11/10 | 11/10 | | |
NCT01022541 / 2005-004505-29: Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer |
|
|
| Completed | 2 | 47 | Europe | Capecitabine, Xeloda, Oxaliplatin, Eloxatin, Bevacizumab, Avastin, Liver metastasectomy | Royal Marsden NHS Foundation Trust, Roche Pharma AG | Metastatic Colorectal Cancer | 12/10 | 02/15 | | |
|
|
| Completed | 2 | 30 | Europe | Irinotecan, CPT-11, Campto, Leukovorin, LV, Oxaliplatin, LoHP, Eloxatin, 5-FLUOROURACIL, 5-FU, Cetuximab, Erbitux | University Hospital of Crete | Metastatic Colorectal Cancer | 12/10 | 12/10 | | |
NCT00675012 / 2007-003668-24: NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 24 | Europe | NGR-hTNF, Oxaliplatin, capecitabine | AGC Biologics S.p.A. | Colon Cancer | 12/10 | 05/13 | | |
NCT00636610: A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 199 | NA | Vismodegib 150 mg, GDC-0449, Erivedge, Placebo to vismodegib, Bevacizumab, Modified FOLFOX, FOLFIRI | Genentech, Inc. | Metastatic Colorectal Cancer | 12/10 | 12/10 | | |
HEARTO, NCT01348412: Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure |
|
|
| Completed | 2 | 31 | Europe | oxaliplatin, raltitrexed, other intravenous chemotherapy drugs | Centre Georges Francois Leclerc, National Cancer Institute, France, Hospira, now a wholly owned subsidiary of Pfizer | Colorectal Cancer, Liver Metastases | 12/10 | 04/18 | | |
NCT00615056 / 2007-006283-30: A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen |
|
|
| Completed | 2 | 171 | Japan, US, Canada, Europe, RoW | Bevacizumab (avastin), FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU]), AG-013736 (axitinib), FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU]), FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU]) | Pfizer | Colorectal Neoplasms | 03/11 | 04/12 | | |
|
|
APRIORI, NCT01126866: Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy |
|
|
| Terminated | 2 | 35 | Europe | intensified chemotherapy (FOLFOXIRI/Bevacizumab) | National Center for Tumor Diseases, Heidelberg, Roche Pharma AG, Pfizer | Colorectal Carcinoma | 03/11 | 06/11 | | |
| Completed | 2 | 268 | Europe, RoW | aflibercept, ZALTRAP™, AVE0005, oxaliplatin, 5-FU, Folinic Acid | Sanofi | Colorectal Neoplasms, Neoplasm Metastasis | 04/11 | 01/12 | | |
|
| Completed | 2 | 48 | Canada, Europe | IMC-1121B (ramucirumab), ramucirumab, LY3009806, Oxaliplatin, Folinic acid, 5-FU | Eli Lilly and Company | Colorectal Carcinoma | 04/11 | 08/11 | | |
|
NCT00544349: Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery |
|
|
| Completed | 2 | 45 | Europe | cetuximab, fluorouracil, leucovorin calcium, oxaliplatin | Gustave Roussy, Cancer Campus, Grand Paris | Colorectal Cancer, Metastatic Cancer | 05/11 | | | |
|
NCT00660582: FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor |
|
|
| Completed | 2 | 152 | Europe | Cetuximab (Erbitux), Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid | Per Pfeiffer, Odense University Hospital | Metastatic Colorectal Cancer | 05/11 | 02/13 | | |
|
NCT00100841: Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer |
|
|
| Completed | 2 | 66 | US | cetuximab, C225, C225 monoclonal antibody, IMC-C225, MOAB C225, monoclonal antibody C225, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU | National Cancer Institute (NCI) | Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Stage IV Colon Cancer, Stage IV Rectal Cancer | 07/11 | 07/11 | | |
| Completed | 2 | 111 | Europe | FOLFIRI regimen, fluorouracil, irinotecan hydrochloride, leucovorin calcium, zibotentan, laboratory biomarker analysis, pharmacogenomic studies | Cardiff University | Colorectal Cancer | 07/11 | 09/12 | | |
| Terminated | 2 | 2 | US | FOLFOX, oxaliplatin, leucovorin, 5-fluorouracil, total mesorectal excision (TME), Total Mesorectal Excision | Beth Israel Medical Center, St. Luke's-Roosevelt Hospital Center | Rectal Neoplasms | 08/11 | 08/11 | | |
NCT01270438: Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | FOLFOX regimen, gamma-secretase/Notch signalling pathway inhibitor RO4929097, bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil | National Cancer Institute (NCI) | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer | 08/11 | 08/13 | | |
| Completed | 2 | 37 | Europe | FOLFOXIRI + Panitumumab | Gruppo Oncologico del Nord-Ovest | Metastatic Colo-rectal Cancer | 10/11 | | | |
|
NCT00700570: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 45 | RoW | bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 11/11 | 11/11 | | |
FOSCO, NCT00889343 / 2008-000803-26: Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer |
|
|
| Terminated | 2 | 101 | Europe | Sorafenib, Nexavar, Placebo, Oxaliplatin or Irinotecan, Leucovorin, 5-Fluorouracil | AIO-Studien-gGmbH | Colorectal Neoplasms | 11/11 | 12/12 | | |
| Terminated | 2 | 9 | Europe | Oxaliplatin, Capecitabine, Panitumumab, Oxaliplatin, Capecitabine | AIO-Studien-gGmbH, iOMEDICO AG | Colorectal Neoplasms | 11/11 | 03/12 | | |
